A Calgary-based company called Solvet has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA) to sell its equine ivermectin product in the United States to combat screwworm. The product is an aqueous-based solution, unique for being more concentrated and easier to administer compared to traditional paste forms. Solvet, established in 2009 by two former University of Calgary professors, has evolved into one of Canada’s prominent veterinary pharmaceutical companies.
Ivermectin, known for its effectiveness against various parasites, including screwworm, has been a crucial tool in pest management. Female screwworm flies lay eggs on wounds of mammals, leading to severe tissue damage and potential fatality. The eradication of screwworm in North America was successfully achieved using the sterile insect technique, where sterile males were released to prevent reproduction.
However, screwworm infestations have resurfaced, prompting concern in the southern U.S. In response to recent cases, Solvet’s ivermectin liquid has been authorized for short-term prevention of screwworm in horses by the FDA. This specific use is essential in regions like Texas where the risk of screwworm infestation is prevalent. The authorization aims to protect animals from severe tissue damage caused by screwworm larvae.
Veterinarian John Gilleard from the University of Calgary emphasizes the importance of judicious use of the product to avoid resistance in parasites. While Canada currently faces a low risk of screwworm infestation due to its climate, authorities continue to monitor the situation closely. Solvet views this authorization as an opportunity for growth, aiming to expand its market reach and contribute to the economy of Alberta through its innovative products.